FDA Approves PHENTERMINE AND TOPIRAMATE — Prasco Laboratories

On December 12, 2024, Prasco Laboratories announced the approval of the phentermine and topiramate immediately extended-release capsule product, enabling the company to execute on its strategy to expand its market share within the FDA-approved weight-loss sector. This additional access is anticipated to drive new revenue streams and strengthen Prasco's position as a key competitor in the evolving obesity treatment landscape.